Brainstorm Cell Ther (BCLI) 0.3200 $BCLI
BrainStorm Receives Notice of Allowance on US Patent
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."
BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
eTeligis - Tue Jul 15, 10:04AM CDT
Petach Tikvah, Israel, New York, NY, United States, via eTeligis Inc., 07/15/2014 - - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin enrolling patients into the Company's randomized, double-bling placebo-controlled phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS). UMass Memorial is the second site to become active of the three sites participating in this trial. The other two clinical sites participating in the multi-center trial are Massachusetts General Hospital (MGH), which began enrolling patients into the trial last month, and the Mayo Clinic, which is expected to become active in the third quarter of 2014. The Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture NurOwn cells for MGH and UMass Memorial.
BrainStorm publishes study of preclinical multidose in mice of NurOwn
M2 - Fri Jul 11, 7:01AM CDT
Adult stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI) announced on Friday that it has published a preclinical study about the safety of single and repeated intramuscular administration of NurOwn, its proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors, in the Clinical and Translational Medicine journal.
BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn
Marketwire - Fri Jul 11, 6:08AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journal Clinical and Translational Medicine. This paper describes the safety of single and repeated intramuscular administration of NurOwn, the Company's proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors. NurOwn is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has demonstrated efficacy in preclinical models of a variety of neurodegenerative diseases, including Parkinson's disease, Huntingon's disease and multiple sclerosis. The results published today are important because they establish that repeated doses of NurOwn are safe in mice and more specifically, that mice generate only minimal immune response after repeated exposure to NurOwn, which are human cells. These data will help support the use of multiple doses of NurOwn in future clinical trials.
OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell Therapeutics, Inc., Advanced Cell Technology, Inc.
PR Newswire Europe - Tue Jul 01, 7:01AM CDT
LONDON, July 1, 2014 /PRNewswire/ --
BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem Cells
Marketwire - Fri Jun 27, 8:50AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and tissue therapy, announced today that they have reached an important milestone in their technology collaboration, successfully constructing an Alpha prototype of a customized bioreactor for BrainStorm's NurOwn(TM) neurotrophic-factor secreting mesenchymal stem cells. The proprietary bioreactor under development will provide BrainStorm with large-scale manufacturing capabilities, enabling it to achieve economies of scale for its autologous stem cell product.
BrainStorm Cell Therapeutics Raises $10.5 Million in Private Placement Financing
Marketwire - Fri Jun 13, 8:30AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System therapeutics, today announced that it has entered into definitive agreements with a group of investors, including several healthcare-focused funds, in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, BrainStorm will receive gross proceeds of $10.5 million, resulting from the issuance and sale of 42.0 million shares of common stock at a price per share of $0.25, a 15% discount to the 30 day volume-weighted average price of $0.294. The purchasers will also receive warrants to purchase up to 42.0 million shares of common stock at an exercise price of $0.348 per share. The warrants are exercisable immediately upon closing of the private placement and have a term of three years.
BrainStorm Expands Pipeline With Initiation of Pre-Clinical Study in Autism
Marketwire - Tue Jun 10, 6:10AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has initiated a study in a mouse model of autism at the Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, under the direction of Professor Daniel Offen. The study will explore the effects of the company's "MSC-NTF" cells on mouse behavior.
BrainStorm Cell Therapeutics Appoints Tony Fiorino, MD, PhD as Chief Executive Officer
Marketwire - Mon Jun 09, 6:30AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has appointed Tony Fiorino, MD, PhD as its new Chief Executive Officer (CEO).
First Patient Enrolled in BrainStorm's Phase II ALS Trial at Massachusetts General Hospital
Marketwire - Fri Jun 06, 7:40AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in Boston.
BrainStorm Hosting Conference Call to Update Shareholders on Major Developments
Marketwire - Thu Jun 05, 7:52AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, June 10, 2014 at 8:45 a.m. Daylight Saving Time (DST), 15:45 Israel Daylight Time (IDT). Mr. Chaim Lebovits, BrainStorm's President, and other senior management members will provide an update to shareholders and discuss major company developments.
BrainStorm Receives Notice of Allowance on US Patent
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."
BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
eTeligis - Tue Jul 15, 10:04AM CDT
Petach Tikvah, Israel, New York, NY, United States, via eTeligis Inc., 07/15/2014 - - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin enrolling patients into the Company's randomized, double-bling placebo-controlled phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS). UMass Memorial is the second site to become active of the three sites participating in this trial. The other two clinical sites participating in the multi-center trial are Massachusetts General Hospital (MGH), which began enrolling patients into the trial last month, and the Mayo Clinic, which is expected to become active in the third quarter of 2014. The Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture NurOwn cells for MGH and UMass Memorial.
BrainStorm publishes study of preclinical multidose in mice of NurOwn
M2 - Fri Jul 11, 7:01AM CDT
Adult stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI) announced on Friday that it has published a preclinical study about the safety of single and repeated intramuscular administration of NurOwn, its proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors, in the Clinical and Translational Medicine journal.
BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn
Marketwire - Fri Jul 11, 6:08AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journal Clinical and Translational Medicine. This paper describes the safety of single and repeated intramuscular administration of NurOwn, the Company's proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors. NurOwn is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has demonstrated efficacy in preclinical models of a variety of neurodegenerative diseases, including Parkinson's disease, Huntingon's disease and multiple sclerosis. The results published today are important because they establish that repeated doses of NurOwn are safe in mice and more specifically, that mice generate only minimal immune response after repeated exposure to NurOwn, which are human cells. These data will help support the use of multiple doses of NurOwn in future clinical trials.
OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell Therapeutics, Inc., Advanced Cell Technology, Inc.
PR Newswire Europe - Tue Jul 01, 7:01AM CDT
LONDON, July 1, 2014 /PRNewswire/ --
BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem Cells
Marketwire - Fri Jun 27, 8:50AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, and Octane Biotech Inc., a Canadian firm that focuses on clinical systems for cell and tissue therapy, announced today that they have reached an important milestone in their technology collaboration, successfully constructing an Alpha prototype of a customized bioreactor for BrainStorm's NurOwn(TM) neurotrophic-factor secreting mesenchymal stem cells. The proprietary bioreactor under development will provide BrainStorm with large-scale manufacturing capabilities, enabling it to achieve economies of scale for its autologous stem cell product.
BrainStorm Cell Therapeutics Raises $10.5 Million in Private Placement Financing
Marketwire - Fri Jun 13, 8:30AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System therapeutics, today announced that it has entered into definitive agreements with a group of investors, including several healthcare-focused funds, in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, BrainStorm will receive gross proceeds of $10.5 million, resulting from the issuance and sale of 42.0 million shares of common stock at a price per share of $0.25, a 15% discount to the 30 day volume-weighted average price of $0.294. The purchasers will also receive warrants to purchase up to 42.0 million shares of common stock at an exercise price of $0.348 per share. The warrants are exercisable immediately upon closing of the private placement and have a term of three years.
BrainStorm Expands Pipeline With Initiation of Pre-Clinical Study in Autism
Marketwire - Tue Jun 10, 6:10AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has initiated a study in a mouse model of autism at the Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, under the direction of Professor Daniel Offen. The study will explore the effects of the company's "MSC-NTF" cells on mouse behavior.
BrainStorm Cell Therapeutics Appoints Tony Fiorino, MD, PhD as Chief Executive Officer
Marketwire - Mon Jun 09, 6:30AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has appointed Tony Fiorino, MD, PhD as its new Chief Executive Officer (CEO).
First Patient Enrolled in BrainStorm's Phase II ALS Trial at Massachusetts General Hospital
Marketwire - Fri Jun 06, 7:40AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient was enrolled in its Phase II ALS trial at Massachusetts General Hospital (MGH) in Boston.
BrainStorm Hosting Conference Call to Update Shareholders on Major Developments
Marketwire - Thu Jun 05, 7:52AM CDT
BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will hold a conference call on Tuesday, June 10, 2014 at 8:45 a.m. Daylight Saving Time (DST), 15:45 Israel Daylight Time (IDT). Mr. Chaim Lebovits, BrainStorm's President, and other senior management members will provide an update to shareholders and discuss major company developments.
